10-K: Telomir Pharma Advances Telomir-1, Plans Merger with TELI

Telomir Pharmaceuticals, a preclinical-stage biotech, reports progress on its lead compound Telomir-1 and announces a merger with TELI Pharmaceuticals to consolidate global intellectual property rights, despite ongoing net losses and a going concern warning.

Summary

• Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics for aging and age-related diseases, including oncology.
• The lead investigational compound, Telomir-1 (Zn-Telomir), is designed to modulate intracellular metal balance, particularly iron, copper, calcium, and zinc.
• Preclinical studies have shown Telomir-1's activity in modulating oxidative stress, mitochondrial function, epigenetic regulation, telomere integrity, and demonstrating anti-tumor effects in various models.
• Favorable results from IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for Telomir-1 have been reported, showing it was well tolerated without dose-limiting toxicities.
• The company targets submitting an Investigational New Drug (IND) application in 2026 and, if effective, commencing a Phase 1/2 clinical trial thereafter.
• Telomir has entered into a Merger Agreement with TELI Pharmaceuticals, Inc., a related private company, to consolidate U.S. and non-U.S. rights to Telomir-1 under a single public company structure, subject to shareholder approval.
• As a result of the merger, Telomir will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1.
• The company reported net losses of $10.4 million for the year ended December 31, 2025, and $16.5 million for 2024.
• An accumulated deficit of $41.0 million was reported as of December 31, 2025.
• Cash and cash equivalents were approximately $7.3 million as of December 31, 2025, which is expected to fund operations and initial clinical development activities into the first quarter of 2027.
• The independent registered public accounting firm has raised substantial doubt about the company's ability to continue as a going concern.
• The company relies heavily on third parties for conducting preclinical studies, clinical trials, and manufacturing.
• The CEO and CFO are employed on a part-time basis, which may lead to conflicts of interest.
• Significant related party transactions exist, including licensing Telomir-1 from MIRALOGX (owned by a trust established by the company's founder) and equity investments from affiliated trusts.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, early-stage biotech with promising preclinical data but significant financial challenges, including a going concern warning and heavy reliance on future financing and related party transactions. The proposed merger aims to consolidate IP but also introduces additional complexities and related party conflicts.

Positives

• Favorable results from IND-enabling GLP toxicology and safety pharmacology studies for Telomir-1, indicating it was well tolerated without treatment-related adverse or dose-limiting toxicities.
• Telomir-1 demonstrated promising biological activity in preclinical models for Wilsons disease, Type 2 diabetes, age reversal, Progeria, oxidative stress, and oncology.
• The proposed merger with TELI Pharmaceuticals will consolidate worldwide intellectual property rights for Telomir-1 under Telomir, simplifying global development efforts.
• Successful capital raises in 2025, including $6.5 million from At The Market (ATM) financings and $3 million from The Bayshore Trust (a related party).
• Cash and cash equivalents increased significantly to $7.3 million by December 31, 2025, from $1.3 million in 2024.
• Net loss decreased from $16.5 million in 2024 to $10.4 million in 2025.
• Management believes internal control over financial reporting was effective as of December 31, 2025, and remediated previously identified material weaknesses.

Negatives

• The company is an early development-stage enterprise with no revenues to date.
• An accumulated deficit of $41.0 million as of December 31, 2025, highlights significant historical losses.
• The independent auditor's report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.
• Additional financing will be required to continue operations beyond the first quarter of 2027 and to fully implement the business strategy.
• The CEO and CFO are not employed on a full-time basis, which may lead to instances where they are not immediately available and could create conflicts of interest.
• The company's intellectual property for Telomir-1 is licensed from MIRALOGX, a related party, and the company does not own the underlying patent application.
• MIRALOGX has retained foreign patent rights for Telomir-1, potentially allowing for the development of a competing product outside the U.S.
• The proposed merger with TELI Pharmaceuticals involves several inherent conflicts of interest due to common beneficial owners and related parties.
• TELI Pharmaceuticals, the merger target, has a limited operating history, no revenues, significant liquidity needs, and does not own rights to Telomir-1, only licenses international rights from MIRALOGX with royalty obligations.

Risks

• Ability to obtain and maintain regulatory approval of product candidates.
• Ability to successfully commercialize and market product candidates, if approved by the FDA.
• Reliance on third-party suppliers, manufacturers, and other service providers and their ability to perform adequately.
• Potential market size, opportunity, and growth potential for product candidates, if approved by the FDA.
• Ability to obtain additional funding for operations and development activities.
• Accuracy of estimates regarding expenses, capital requirements, and needs for additional financing.
• Initiation, timing, progress, and results of pre-clinical studies and clinical trials, and research and development programs.
• Timing of anticipated regulatory filings.
• Future expenses, capital requirements, and need for additional financing.
• Ability to retain the continued service of key professionals and to identify, hire, and retain additional qualified professionals.
• Ability to advance product candidates into, and successfully complete, clinical trials.
• Ability to recruit and enroll suitable patients in clinical trials.
• Timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives.
• Pricing and reimbursement of product candidates, if approved by the FDA.
• Implementation of business model and strategic plans for business, product candidates, and technology.
• Scope of protection for intellectual property rights covering product candidates and technology.
• Developments relating to competitors and the industry.
• Development of major public health concerns, including pandemics, and their future impact on business operations and funding requirements.
• Ability to successfully integrate and utilize acquired assets, licenses, and businesses.
• Dependence on licensed rights to Telomir-1; any loss of these rights could prevent product sales.
• Risk of third parties claiming intellectual property infringement.
• Early development-stage company with no revenues and substantial doubt about its ability to continue as a going concern.
• Limited operating history makes it difficult to accurately evaluate operations.
• Operating results may fluctuate, negatively impacting growth and revenue.
• Has not achieved a profit and may not in the near future, if at all.
• Certain executive officers are not employed on a full-time basis, potentially leading to conflicts of interest.
• Conflicts of interest may arise between Telomir and MIRALOGX, a related party.
• Future success depends largely on Telomir-1, which requires significant capital and years of clinical development.
• Product candidates may not receive regulatory approval or be successfully commercialized.
• Results of pre-clinical studies and earlier clinical trials are not necessarily predictive of future results.
• Limited marketing experience and no anticipated sales force or distribution capabilities.
• Difficulties in managing organizational growth and executing growth strategy.
• Intense competition from companies with greater resources and experience.
• Significant and increasing liquidity needs, requiring additional funding.
• Clinical trials are expensive, time-consuming, uncertain, and susceptible to change, delay, or termination.
• Results of clinical trials are open to differing interpretations.
• Failure to comply with existing regulations could harm reputation and operating results.
• Regulatory approval processes with the FDA are lengthy and inherently unpredictable.
• High rate of failure for drug candidates proceeding through clinical trials.
• Violation of federal or state fraud and abuse laws could lead to penalties or suspension from healthcare programs.
• Serious adverse events or other safety risks could require abandonment of development, delay approval, limit label scope, or cause product recall.
• Reliance on third parties to conduct clinical trials for product candidates.
• Existing collaboration arrangements and any future ones may not be successful.
• Reliance on a third party for the manufacture of Telomir-1 for clinical development.
• Future sales of common stock, or the perception of future sales, may cause the market price to decline.
• Speculative nature of an investment in the company; investors may lose their entire investment.
• Certain founding stockholders, officers, and directors control a substantial interest and may influence stockholder votes.
• Requirements of being a public company may strain resources and divert management's attention.
• Emerging growth company status and reduced reporting requirements could make shares less attractive to investors.
• Smaller reporting company status may lead to reduced reporting requirements.
• Failure to maintain compliance with Nasdaq Listing Rules could result in delisting.
• Delisting from Nasdaq may cause securities to become subject to SEC's penny stock rules.
• Provisions of Florida law and corporate documents may have anti-takeover effects.
• Amended and restated bylaws designate Florida state courts as the exclusive forum for most disputes and federal district courts for Securities Act claims.
• Securities or industry analysts may not regularly publish reports, causing price or trading volumes to decline.
• Future offerings of equity securities will likely dilute proportionate interest.
• Issuance of preferred stock in the future could make it difficult for another company to acquire Telomir.
• Never declared or paid cash dividends and does not anticipate paying any in the foreseeable future.
• Risks related to the planned merger with TELI Pharmaceuticals, Inc., including TELI's limited operating history, significant liquidity needs, lack of revenues or profit, and its reliance on a license for Telomir-1.
• TELI's product candidates, if approved, may not achieve expected market acceptance.
• If the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate reimbursement levels, revenue and prospects for profitability will suffer.
• TELI expects to face intense competition, often from companies with greater resources and experience.
• Several conflicts of interest are inherent in the merger due to related party ownership.
• Following the merger, TELI shareholders may potentially own a majority of TELO.
• There is no assurance when or if the merger will be completed, subject to conditions and potential litigation/regulatory challenges.
• The price of TELO's common stock is subject to fluctuations.
• Cybersecurity threats, including operational risks, intellectual property theft, fraud, extortion, harm to employees, and violation of data privacy or security laws, could disrupt business.

Future Outlook

The company is targeting IND submission in 2026 and, if the IND becomes effective and other conditions are satisfied, plans to initiate a Phase 1/2 clinical trial thereafter. The timing of these activities is subject to change and may be delayed. The company expects to incur significant losses and increased research and development expenses as Telomir-1 advances through clinical trials and regulatory approvals. Additional financing will be required to continue development beyond the first quarter of 2027 and to fully implement its business strategy. There is no assurance that preclinical findings will translate into safety, efficacy, disease modification, or therapeutic benefit in humans.

Management Comments

• Management believes its research strategy targets fundamental cellular processes associated with disease progression and functional decline.
• Management believes Telomir-1's approach targeting intracellular metal homeostasis and related cellular pathways represents a differentiated scientific strategy.
• Management is committed to revolutionizing treatments for age-related and chronic diseases by addressing their root causes and paving the way for transformative healthcare solutions.
• Management believes the terms obtained or consideration paid/received in related party transactions were comparable to arms-length transactions with unrelated third parties.

Industry Context

StockSavvy.ai notes that Telomir Pharmaceuticals operates in the highly competitive biotechnology and pharmaceutical industries, targeting large and growing markets such as anti-aging ($91.05 billion in 2024, projected to $160.24 billion by 2031), Type 2 Diabetes ($30.47 billion in U.S. in 2022), Age-related Macular Degeneration (AMD) ($18 billion by 2030), oncology ($74.1 billion in 2023, projected to $180.12 billion by 2033), and antiviral drugs ($49.8 billion in 2022, projected to $71.1 billion by 2032). The company's focus on metal-ion dysregulation and oxidative stress offers a differentiated scientific strategy in these crowded fields, aiming to address root causes rather than just symptoms.

Comparison to Industry Standards

• The annual treatment cost for Progeria exceeds $1 million, based on the price of Zokinvy (lonafarnib), the FDA-approved drug for the condition.
• Treatments for Wilsons disease, like Syprine (trientine hydrochloride), can cost approximately $300,000 per year.
• The company's preclinical results for Telomir-1 in various disease models (Wilsons, Type 2 Diabetes, Progeria, Oncology) are presented as promising, but no direct comparisons to specific competitor drug candidates or their clinical trial results are provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• No material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse to the company or any of its subsidiaries.
• No director or executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years.
• No current director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the past ten years.
• No current director or executive officer has been the subject of any order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities during the past ten years.
• No current director or officer has been found by a court to have violated a federal or state securities or commodities law during the past ten years.
• The company may be named in claims arising in the ordinary course of business.
• The company anticipates expending significant financial and managerial resources in the defense of its intellectual property rights in the future if it believes its rights have been violated.
• The company anticipates expending significant financial and managerial resources to defend against claims that its products and services infringe upon the intellectual property rights of third parties.
• The proposed Merger and related transactions may be challenged in court by shareholders or other interested parties, potentially leading to lawsuits alleging breaches of fiduciary duties.
• Government agencies, including antitrust authorities, may seek to block, delay, or impose conditions on the Merger.

Related Party Transactions

• The company licenses the U.S. patent rights for Telomir-1 in human and animal applications from MIRALOGX, LLC, an intellectual property development and holding company owned by The Bay Shore Trust (established by the company's founder, Jonnie R. Williams, Sr.).
• The MIRALOGX License Agreement provides for an 8% royalty on net sales of Licensed Products and non-royalty bearing milestone revenue, with no upfront, execution, or milestone payments made to date.
• MIRALOGX controls the prosecution of patent applications for Telomir-1, and the company reimburses MIRALOGX for patent prosecution and maintenance costs.
• Advances totaling $1.7 million from MIRALOGX and The Starwood Trust (another trust established by the founder) were converted into 837,841 shares of common stock on November 30, 2023.
• The company incurred $0.4 million in related party travel costs in 2024 under an Agreement for Shared Lease Costs with MIRALOGX and MIRA Pharmaceuticals, Inc., for an aircraft lease (Supera Aviation I LLC, owned by Starwood Trust); this agreement was terminated in April 2024.
• On September 24, 2024, the company entered into an unsecured Promissory Note and Loan Agreement (Starwood Note) with The Starwood Trust, allowing it to borrow up to $5 million at 7% simple interest; no amounts have been borrowed as of December 31, 2025.
• On December 9, 2024, The Starwood Trust purchased 142,857 shares of unregistered common stock from the company for $1.0 million.
• On May 19, 2025, the company raised $3 million in equity financing through a direct investment by The Bayshore Trust, issuing 1,000,001 restricted shares of common stock at $3.00 per share.
• A common stock purchase warrant was issued to The Bay Shore Trust on June 15, 2023, granting the right to purchase up to 2,439,025 shares at an exercise price of $3.73 per share, expiring five years after grant.
• On May 27, 2025, 400,000 fully vested common shares were granted for services to the company's CEO, Erez Aminov (son-in-law of the founder), valued at $840,000.
• Erez Aminov and The Bayshore Trust have significant beneficial ownership interests in both Telomir and TELI, creating potential conflicts of interest in the proposed merger.
• TELI's international license for Telomir-1 is also from MIRALOGX, with an 8% royalty and a minimum annual royalty of $250,000.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises, the influence of founding stockholders and management on corporate decisions, and risks of delisting from Nasdaq. The speculative nature of the investment means a high risk of losing the entire investment. The merger could result in current TELI shareholders owning a majority of the combined company.
• Employees (currently only two part-time executives) and contractors are critical for operations, and the company faces intense competition for qualified personnel.
• Customers and patients could potentially benefit from novel therapeutics for age-related diseases and oncology if Telomir-1 is successfully developed and approved, but face the risk of product candidates failing clinical trials or not receiving regulatory approval.
• Creditors face increased risk due to the company's going concern warning and substantial accumulated deficit, raising concerns about its ability to meet financial obligations.
• Suppliers and partners, particularly third-party CROs and manufacturers, are crucial for the company's development programs, and their performance or disruptions due to geopolitical events could impact the company's progress.

Next Steps

• Submit an Investigational New Drug (IND) application in 2026.
• Initiate a Phase 1/2 clinical trial thereafter, if the IND becomes effective and other conditions are satisfied.
• Continue advancing regulatory preparation and development activities for Telomir-1.
• Optimize manufacturing processes to produce GMP-grade Telomir-1 for IND-enabling activities and potential future clinical trials.
• Finalize the initial clinical development program for Telomir-1 and identify the most impactful indication for its initial IND application.
• Seek shareholder approval for the merger with TELI Pharmaceuticals.
• Certain TELI shareholders will agree to provide $2 million upon FDA acceptance of an IND application for Telomir-1, and $2 million upon initiation of a Phase 1/2 study.
• Continue evaluating the broader therapeutic potential of Telomir-1 across multiple disease areas, including Wilsons disease, Type 2 diabetes, age-related macular degeneration, oncology, epigenetic regulation, metal toxicity, and DNA methylation analysis.
• Plan further studies in a Progeria human cell line in collaboration with Smart Assays.
• Raise additional funds through public or private financing, strategic relationships, or other arrangements to support business operations and future development.

Key Dates

Recommendation

The company presents promising preclinical data for Telomir-1 across multiple significant disease areas and has secured recent financing, which are positive indicators. However, it remains a preclinical-stage company with no revenues, substantial accumulated losses, and a going concern warning from its auditor. The proposed merger with TELI, while consolidating IP, introduces additional complexities and related party conflicts. The path to regulatory approval and commercialization is long, expensive, and uncertain. Investors should hold to monitor progress on IND submission, clinical trials, and the successful integration and financing of the combined entity, while acknowledging the high-risk profile.

Keywords

Telomir-1, biotechnology, preclinical, aging, age-related diseases, oncology, metal ion regulator, oxidative stress, telomere integrity, Wilsons disease, Type 2 diabetes, Progeria, AMD, cancer, IND application, clinical trials, merger, TELI Pharmaceuticals, SEC filing, 10-K, financial reporting, corporate governance, drug development, pharmaceutical, Nasdaq, intellectual property, related party transactions